HIV conversation centers on pill that prevents transmission

John Byrne was born in 1981, a few months before the U.S. Centers for Disease Control and Prevention revealed a new report about “five young, previously healthy, gay men in Los Angeles” suffering from strange infections that had already killed two of them.

That was on June 5. Throughout that summer, doctors across the United States reported similar cases of “GRID” (gay-related immune deficiency) and The New York Times reported on a deadly cancer affecting 41 gay men in New York and California in early July. The next year, the CDC named the new plague AIDS, and gay men in San Francisco and New York City began the first community-based efforts to eradicate its cause, human immunodeficiency virus or HIV.

Condoms were the only reliable defense against contracting HIV then, and AIDS activists fervently encouraged young gay men not to bareback.

More than three decades since those first reports, plenty has improved across the country when it comes to HIV and AIDS. Still, Miami-Dade and Broward counties still claim the highest rates of new HIV infections in the United States. Byrne, publisher of RawStory.com, and others throughout South Florida have begun their own community-based campaigns to address this alarming local trend.

And despite warnings from activists, drug companies and the U.S. government, some young men are dropping the latex in favor of a little blue pill deemed equally effective in preventing the spread of HIV.

The pill, Truvada by Gilead Sciences, has been used for about a decade for HIV treatment. As it turns out, it’s been found to be nearly 100 percent effective in preventing people who are HIV negative from contracting the virus.

“Swallow This” is the slogan for a campaign Byrne recently launched. He is advocating something revolutionary: the widespread use of PrEP or pre-exposure prophylaxis.

“I never really liked condoms. It didn’t feel sexy. It didn’t feel like sex,” says Byrne, who came out at 15 and became sexually active in high school at the height of the AIDS crisis.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below